← Eichor
Condition: Vaccine Response Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Vaccine Response

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Patients With Chronic Renal Failure
NA · 1 location(s) · Centre Hospitalier Universitaire de Nice · NCT06907667Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
Phase 2 · 2 location(s) · University of Maryland, Baltimore · NCT06624839Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk
Phase N/A · 1 location(s) · Institute of Tropical Medicine, Belgium · NCT05879965Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COV
Phase 1 · 1 location(s) · The Methodist Hospital Research Institute · NCT06821100Antibiotics and Vaccine Immune Responses Study
Phase 4 · 1 location(s) · South Australian Health and Medical Research Institute · NCT06148025Butantan-DV Vaccine in Elderly Populations (DEN-04-IB)
Phase 3 · 5 location(s) · Butantan Institute · NCT06891950A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTp
Phase 3 · 10 location(s) · GlaxoSmithKline · NCT07596173Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC
Phase 1 · 1 location(s) · West China Hospital · NCT07565740TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B
Phase 1 · 1 location(s) · University of Maryland, Baltimore · NCT04843852A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rub
Phase 3 · 22 location(s) · GlaxoSmithKline · NCT06855160Registry of Vaccine Responses in Immune Compromised Patients
Phase N/A · 1 location(s) · Laure Pittet, MD-PhD · NCT06463119Systems Investigation of Vaccine Responses in Aging and Frailty
Phase 2 · 1 location(s) · Yale University · NCT05291676COVID-2019 Vaccine Immune Response Base on Single Cell Multi-Omics
Phase N/A · 1 location(s) · RenJi Hospital · NCT04871932A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTp
Phase 3 · 18 location(s) · GlaxoSmithKline · NCT07596199Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
Phase 4 · 1 location(s) · Mercy Medical Center · NCT04588077Comprehensive Characterization of Immune Response Induced by Adjuvanted Glycoprotein E (gE)-Based Recombinant VAccine Zo
Phase N/A · 1 location(s) · Fondazione IRCCS Policlinico San Matteo di Pavia · NCT07534007HPV Vaccine Reduced Dose
Phase 4 · 1 location(s) · Emory University · NCT06799494VRC 900: Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older
Phase N/A · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT01132859Intradermal Influenza Vaccination
EARLY_Phase 1 · 1 location(s) · Yale University · NCT06067555A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine,
Phase 3 · 17 location(s) · GlaxoSmithKline · NCT07406360Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
Phase 2 · 1 location(s) · University of California, Davis · NCT02232191Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a
Phase 3 · 1 location(s) · Invivyd, Inc. · NCT07655180Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant Recipients
NA · 1 location(s) · Central Adelaide Local Health Network Incorporated · NCT06262776A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.
Phase 3 · 5 location(s) · Pfizer · NCT07543380Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases
Phase N/A · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT05078905A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Heal
Phase 3 · 6 location(s) · GlaxoSmithKline · NCT06806137Description of the Immune Response to Yellow Fever Vaccination
NA · 1 location(s) · Institut Pasteur · NCT06718127A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to
Phase 3 · 97 location(s) · GlaxoSmithKline · NCT06740630How Gut Health Affects Immune Responses to the Oral Rotavirus Vaccine in Adults in Zambia
Phase N/A · 1 location(s) · Centre for Infectious Disease Research in Zambia · NCT07626606Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adoles
Phase 3 · 44 location(s) · Pfizer · NCT07660198
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.